Indegene Ltd

Indegene Ltd share price softened by 0.96% to Rs 594.0 after the company's net profit slipped by 3.36% to Rs 112.3 crore, while revenue from operations slightly gained 5.57% to Rs 1122.3 crore in Q3FY26 over Q2FY26. The market capitalization of Healthcare Research, Analytics & Technology industry group stocks on BSE stood at Rs 40872.28 crore, gaining 8.73%. It has improved by 5.49% over last one week and crept higher by 1.53% in last one month while the market capitalization of Indegene Ltd has inched up 3.94% and 15.38% in the same period respectively. Profit before tax (PBT) of Indegene Ltd stood at Rs 147.4 crore in Q3 FY26, climbing 10.74% year-on-year, and slipping 3.47% quarter-on-quarter. EBITDA came in at Rs 171 crore, surging by 41.19% YoY and jumping 17.56% sequentially. Total expenses posted a minor rise of 5.36% to Rs 983.0 crore in Q3FY26 over Q3FY25. During the quarter, employee benefits expense was at Rs 681.7 crore, inching up 3.43% YoY. For the TTM ended FY26, revenue from operations jumped by 23.64% to Rs 3510.5 crore, while net profit slipped by 1.38% to Rs 401.1 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 47230% to Rs 547.0 crore, and PBT softened 2.65% to Rs 525.0 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 650.8 crore in FY26, as against Rs 441.9 crore in FY25. Indegene Ltd surged by 8.68% in last one year, significantly outperforming the benchmark BSE Sensex which has reduced by 12.76% during the same period.

Indegene Limited announced the incorporation of a step-down wholly owned subsidiary, INDEGENE PORTUGAL, UNIPESSOAL LDA, on October 23, 2026, according to a regulatory filing with the BSE Limited and National Stock Exchange of India Limited. Indegene Ireland Limited, a wholly owned subsidiary of Indegene Limited, holds 100% of the share capital of the newly incorporated entity, which will focus on services for the life sciences, healthcare, and biopharmaceutical sectors, as well as corporate services and content development.

Indegene Limited announced that Mark Francis Dzialga has resigned from his position as Non-Executive - Non Independent Director, effective October 29, 2026, due to the sale of Brighton Park Capital’s entire shareholding in the company. Dzialga, whose Director Identification Number is 00955485, will also cease to be a member of the Nomination and Remuneration Committee and Investment Committee of the Board on the same date.

Indegene Limited informed the BSE Limited and National Stock Exchange of India Limited that MUFG Intime India Private Limited, formerly Link Intime India Private Limited, issued a certificate confirming compliance under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026.

Indegene Limited announced that its board of directors approved the allotment of 16,110 equity shares under its ESOP Scheme 2020, which will rank pari-passu with existing shares, and an amendment to the company’s Prevention of Sexual Harassment Policy on October 5, 2026.

Indegene Limited will hold a board meeting on Thursday, October 29, 2026, to approve the unaudited consolidated and standalone financial results for the quarter and half year ended September 30, 2026, according to a regulatory filing. The company also announced that the trading window for securities will be closed from October 1, 2026, and will reopen 48 hours after the declaration of the financial results.

Indegene Limited informed the BSE Limited and National Stock Exchange of India Limited that the trading window for dealing in the company's securities will be closed from Thursday, October 01, 2026, in connection with the finalization and approval of financial results (standalone and consolidated) for the quarter and half year ended September 30, 2026, and will reopen 48 hours after the results are disseminated.

Indegene Limited announced that the merger of Indegene Healthcare Germany GmbH and Trilogy Writing & Consulting GmbH, both indirect wholly owned subsidiaries of Indegene Limited in Germany, was registered with the Commercial Register of the Local Court (Amtsgericht) of Frankfurt am Main on September 9, 2026, making the merger effective on the same date. Following the merger, Trilogy Writing & Consulting GmbH became Indegene Healthcare Germany GmbH, and the combined entity is projected to have a revenue of Euro 20,100,000 for fiscal year 2026-27, with the company stating the reorganization has no material impact on its business operations, shareholding pattern, or financial position.

Indegene Limited announced that shareholders approved the appointment of Ms. Jill Mary De Simone (DIN:11483134) as an Independent Director at the company's 28th Annual General Meeting held on August 13, 2026, for a term of three years, effective January 22, 2026.

Net profit of Indegene declined 0.17% to Rs 116.20 crore in the quarter ended June 2026 as against Rs 116.40 crore during the previous quarter ended June 2025. Sales rose 39.73% to Rs 1063.10 crore in the quarter ended June 2026 as against Rs 760.80 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales1063.10760.80 40 OPM %16.3920.41 - PBDT196.80173.70 13 PBT152.70152.10 0 NP116.20116.40 0 Powered by Capital Market - Live